Table 2 Summary of demographics of adolescent and young adults for immunogenicity comparison (PPS subset).
Adolescent (12-17 years) (N = 334) | Young adults (20-30 years) (N = 210) | All subjects (N = 399) | P-value | |
|---|---|---|---|---|
Age | <0.0001 (Mann–Whitney U test) | |||
Mean (SD) | 14.4 (1.65) | 25.9 (2.74) | 18.8 (6.02) | |
Min–Max | 12.0–17.0 | 20.0–30.0 | 12.0–30.0 | |
Gender, n (%) | 0.1521 (Chi-square test) | |||
Male | 188 (56.3) | 105 (50.0) | 293 (53.9) | |
Female | 146 (43.7) | 105 (50.0) | 251 (46.1) | |
Race, n (%) | ||||
Asian | 334 (100.0) | 210 (100.0) | 544 (100.0) | |
Non-Asian | ||||
BMI (kg/m2), | <0.0001 (Mann–Whitney U test) | |||
Mean (SD) | 21.2 (4.19) | 23.6 (4.09) | 22.1 (4.31) | |
Min–Max | 15.2 ~ 42.3 | 14.4 ~ 40.5 | 14.4 ~ 42.3 | |
BMI group, n (%) | 0.0076 (Chi-square test) | |||
<30 kg/m2 | 323 (96.7) | 192 (91.4) | 515 (94.7) | |
≥30 kg/m2 | 11 (3.3) | 18 (8.6) | 29 (5.3) | |
HIV antibody, n (%) | 0 | 1 (0.5) | 1 (0.2) | 0.3860 (Fisher’s exact test) |
Pre-vaccination neutralizing antibody against wild-type SARS-CoV-2 (≥8), n (%) | 0 | 0 | 0 | |
Pre-vaccination anti-SARS-CoV-2 IgG (≥100), n (%) | 9 (2.7) | 9 (4.3) | 18 (3.3) | 0.3125 (Chi-square test) |
Comorbidity, n (%) | ||||
Any | 6 (1.8) | 6 (2.9) | 12 (2.2) | |
Cardiovascular disease | 0 | 1 (0.5) | 1 (0.2) | |
Cerebrovascular disease | 0 | 0 | 0 | |
COPD | 0 | 0 | 0 | |
Liver cirrhosis | 0 | 0 | 0 | |
Malignancy | 0 | 0 | 0 | |
HbAlc higher than 5.7% DCCT | 6 (1.8) | 5 (2.4) | 11 (2.0) | |
